GlaxoSmithKline (LON: GSK) will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences' subsidiary Dermavent Sciences, Pharmafile reported on Friday.
Dermavent paid an upfront payment of GBP150 for the rights to tapinarof. It has also agreed to pay GSK future milestone payments of an additional GBP100m upon the achievement of prespecified developmental targets.
Completion of the deal will give Dermavent the global rights to the drug in all countries except China.
The drug has been studied as a treatment for psoriasis and atopic dermatitis (eczema). It was found to have demonstrated clinically meaningful results in treating adults with plaque psoriasis in a Phase IIb study involving 227 patients.
A separate double-blind, placebo-controlled Phase IIb study involving 247 patients with atopic dermatitis also resulted in the drug demonstrating efficacy.
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial